Detalles de la búsqueda
1.
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol;
2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38654611
2.
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
Am J Hematol;
2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38856176
3.
Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data.
Future Oncol;
20(15): 981-995, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38231002
4.
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Future Oncol;
20(3): 131-143, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37807952
5.
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Future Oncol;
20(14): 935-950, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38197267
6.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol;
98(5): 720-729, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36708469
7.
Patient perspectives on symptoms, health-related quality of life, and treatment experience associated with relapsed/refractory multiple myeloma.
Support Care Cancer;
30(7): 5859-5869, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35364733
8.
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Ann Hematol;
100(9): 2325-2337, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33970288
9.
Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Future Oncol;
17(26): 3465-3476, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34342494
10.
Real-world treatment patterns and outcomes in non-transplant newly diagnosed multiple Myeloma in France, Germany, Italy, and the United Kingdom.
Eur J Haematol;
105(3): 308-325, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32418256
11.
Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center.
BMC Endocr Disord;
17(1): 49, 2017 Aug 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28778166
12.
The association between biochemical control and cardiovascular risk factors in acromegaly.
BMC Endocr Disord;
17(1): 15, 2017 Mar 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28279153
13.
Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians.
Pituitary;
20(4): 422-429, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28275992
14.
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY.
Endocr Pract;
23(8): 962-970, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28614003
15.
A single question about a respondent's perceived financial ability to pay monthly bills explains more variance in health utility scores than absolute income and assets questions.
Qual Life Res;
25(9): 2233-7, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27000101
16.
IDENTIFICATION OF POTENTIAL MARKERS FOR CUSHING DISEASE.
Endocr Pract;
22(5): 567-74, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-26789346
17.
INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS.
Endocr Pract;
22(11): 1327-1335, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27540880
18.
The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.
J Surg Oncol;
111(8): 935-40, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-26031501
19.
Validation of an ICD-9-based claims algorithm for identifying patients with chronic idiopathic/spontaneous urticaria.
Ann Allergy Asthma Immunol;
114(5): 393-8, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25771155
20.
Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use.
Epilepsy Behav;
44: 40-6, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25635369